Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.
Gillian McGovern
Advertisement
Articles by Gillian McGovern
The study examined the mechanisms of action associated with immune checkpoint inhibitor combination therapies.
Investigators used LIMS to classify melanoma samples as tumors and non-tumors.
According to study authors, this electrical communication between skin cells may have the potential for therapeutic implications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5